ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1360

Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients

Mélanie Rinaudo-Gaujous1, Pierre Miossec2, Vincent Blasco-Baque3, Philippe Gaudin4, Christian Genin1, Thierry Thomas5, Stéphane Paul1 and Hubert Marotte6, 1Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, 2Department of Clinical Immunology and Rheumatology, Immunogenomics and inflammation research unit, Lyon, France, 3Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, 4Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 5INSERM U1059 and University Hospital, Saint-Etienne, France, 6LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: , ,

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose: This study evaluates biological markers of rheumatoid arthritis (RA) severity including matrix metalloproteinase 3 (MMP-3) and Porphyromonas gingivalis (P. gingivalis) serology during infliximab therapy and highlights predictive factors for infliximab response.

Methods: We enrolled 79 RA patients requiring infliximab therapy in this study.  DAS28, anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) Iga and IgM, anti-P. gingivalis antibodies, anti-Prevotella intermedia (P. intermedia) antibodies, and MMP-3 were monitored before and 6 months after the beginning of infliximab therapy. ACPA, RF, MMP-3 anti-P. intermedia antibodies, and anti-P. gingivalis antibodies (LPS specific and whole extract) antibodies were determined by ELISA.

Results: At baseline, ACPA titers are associated with anti-P. gingivalis LPS specific antibodies titers (P<0.01) and anti-P. gingivalis whole extract antibodies titers (P<0.01), but no association has been found between IgM RF and anti-P. gingivalis antibody. Conversely, anti-P. intermedia antibodies are not correlated with ACPA titers, but with IgM RF levels. Anti-P. gingivalis antibodies were not significantly correlated with clinical, biological, or destruction parameters of RA disease. At 6 months of infliximab therapy, MMP-3 levels decrease (P<0.0001), whereas P. gingivalis and anti-P. intermedia antibodies levels increase (P<0.01). DAS28 and inflammation markers (CRP and ESR) also decrease significantly during infliximab therapy (P<0.05), as ACPA levels (P<0.001). Presence of anti-P. gingivalis antibodies at baseline did not influence the treatment outcome. Only high MMP-3 levels at baseline and a decreased of ACPA at 6 months were associated with infliximab efficacy (P<0.01). 

Conclusion: Anti-P. gingivalis is associated with ACPA at baseline suggesting a role of periodontal infection in RA pathogenesis. Unlike anti-P. gingivalis antibodies, MMP-3 level can be a useful marker of the infliximab efficacy in RA patients as well as the evolution of ACPA during treatment.

Disclosure:

M. Rinaudo-Gaujous,
None;

P. Miossec,
None;

V. Blasco-Baque,
None;

P. Gaudin,
None;

C. Genin,
None;

T. Thomas,
None;

S. Paul,
None;

H. Marotte,
None.

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-biomarkers-involved-in-periondontal-disease-including-porphyromonas-gingivalis-antibodies-to-predict-response-to-infliximab-in-rheumatoid-arthritis-patients/